Ixchelsis is a technology company.
Ixchelsis has raised $12.0M across 1 funding round.
Ixchelsis has raised $12.0M in total across 1 funding round.
Ixchelsis has raised $12.0M in total across 1 funding round.
Ixchelsis's investors include Ed Mathers, Pfizer Venture Investments, T1D Fund.
Ixchelsis Ltd is a private, clinical-stage biotechnology company headquartered in Sandwich, Kent, United Kingdom, founded in 2011 and based in Discovery Park.[2][5][6] It develops cligosiban (formerly IX-01), an oxytocin receptor (OXTR) antagonist targeting premature ejaculation (PE), with a pipeline showing this drug in pending status as of late 2025 and a history of positive proof-of-concept clinical results.[3][4][6] The company generates approximately $7 million in revenue with a small team of 2 employees, focusing on biotechnology research and manufacturing.[1]
Ixchelsis serves patients with PE, addressing an unmet need in men's sexual health by modulating oxytocin signaling to improve ejaculatory control.[3][4] While specific growth metrics are limited, it has secured investments and advanced cligosiban through clinical trials, including 6 trials noted in recent data, positioning it as a specialized player in urology therapeutics.[3][4]
Ixchelsis Ltd was established in 2011 in Sandwich, UK, as an independent biotech firm operating from Discovery Park, a hub for life sciences innovation.[2][5][6] Limited public details exist on its founders or key early figures, but the company emerged amid growing interest in oxytocin pathways for reproductive health disorders.[3][4][6]
A pivotal moment came with positive clinical proof-of-concept results for IX-01 (cligosiban) in treating PE, validating its approach and attracting investment.[3][6] Early traction included venture funding, enabling progression to clinical-stage development with ongoing trials as of 2025.[3][4]
Ixchelsis rides the wave of precision medicine in urology and sexual health, where unmet needs in PE—a condition affecting millions—drive demand for novel antagonists like OXTR inhibitors.[3][4] Timing aligns with advances in neuropeptide research, as oxytocin pathways gain traction beyond labor induction into male reproductive disorders.[6]
Market forces favoring Ixchelsis include rising biotech investments in niche therapeutics and PE's large addressable market, underserved by existing options like SSRIs with side effects.[3] It contributes to the UK biotech ecosystem via Discovery Park, influencing smaller-scale innovation in translational medicine and potentially paving the way for oxytocin-based therapies in adjacent areas.[2][4][5]
Ixchelsis is poised for milestones in cligosiban's development, potentially advancing from pending phase to later trials or partnerships, fueled by its validated proof-of-concept.[4][6] Trends like AI-driven drug discovery and personalized urology will shape its path, amplifying small biotechs like Ixchelsis through efficient pipelines and targeted funding.[4]
Its influence may grow via licensing deals or acquisitions if cligosiban succeeds, solidifying its niche in men's health amid expanding biotech M&A. This positions Ixchelsis to deliver on its core promise: transforming PE treatment from symptom management to mechanism-driven solutions.[3][4]
Ixchelsis has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Venture Round in December 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2016 | $12.0M Venture Round | Ed Mathers, Pfizer Venture Investments, T1D Fund |